Ahammune Biosciences Secures $5M for Vitiligo Trials
Ahammune Biosciences raises $5M led by pi Ventures for Phase II trials, expanding R&D for skin disease treatments.
- Latest
- Trending
Ahammune Biosciences raises $5M led by pi Ventures for Phase II trials, expanding R&D for skin disease treatments.
Cagent Vascular's series C financing round has raised over $30m, enabling them to expand their product portfolio and accelerate US ...
Amlan showcased its unique mineral technology at the World Dairy Expo, with trials demonstrating improvements in milk production and animal ...
Diversity in biotechnology and venture capital is crucial for driving innovation and breakthroughs in healthcare, according to Dr. Stanley Lewis. ...
Efforts to diversify biotech venture capital funding could lead to innovation, breakthroughs in healthcare, and improved outcomes for minorities.
Protagenic Therapeutics achieves milestone in Phase I trial for PT00114, a compound for treating stress-related neuro-psychiatric disorders. No adverse reactions ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.